Panacea Biotec eyes $1  billion hexavalent vaccine  market

Panacea Biotec receives USD 24.32 Million Award of Pentavalent Vaccine from U.N. Agencies

Panacea Biotec Announces Launch Of ViLACT For Treatment Of Uncontrolled Type 2 Diabetes Mellitus Patients

Announcement of Key Managerial Appointments

Press Release on Key Highlights of the financial results for quarter ended 30.06.2019

Thank OD and its combinations will now be available under trademark of Sitcom

Panacea Biotec inks Tripartite Agreement with Natco Pharma Ltd. and Breckenridge Pharmaceutical Inc. for manufacturing and supply of Azacitidine injection in the U.S. Market

Panacea Biotec Announces Receipt of Establishment Inspection Report (EIR) from USFDA

Historic Deal between Panacea Biotec & Serum Institute for EasySix Vaccine

Panacea Biotec announces acceptance of its ANDA for Paclitaxel Protein Bound Particles by US FDA